Retatrutide and tirzepatide both sit in the incretin-agonist family of research peptides. Both are 39-amino-acid sequences developed by Eli Lilly, both are studied in vitro for receptor activity at the GLP-1 and GIP receptors. The difference is a third receptor: retatrutide binds glucagon as well. That single change in receptor profile is the reason researchers reach for retatrutide rather than tirzepatide when the experimental question involves the full incretin-glucagon axis.
This guide compares the two molecules across receptor profile, published clinical-trial data, and the practical contexts in which each is used as a research reference compound. It is written for researchers evaluating which peptide to supply for an in vitro program, not for clinical or therapeutic decision-making. All NorexBio material is supplied for research use only and is not intended for human or veterinary use.
Receptor profile
Both peptides act as agonists at the incretin receptors. The difference is whether glucagon is in the mix:
- Tirzepatide, dual agonist: GLP-1 receptor (GLP-1R) + GIP receptor (GIPR). No appreciable activity at the glucagon receptor.
- Retatrutide, triple agonist: GLP-1R + GIPR + glucagon receptor (GCGR). The glucagon-receptor activity is the differentiator.
In receptor-binding studies, retatrutide's glucagon-receptor potency is intentionally tuned lower than its GLP-1R potency, so the molecule is described as a balanced triple-agonist rather than a glucagon-dominant compound. The clinical research interest in the glucagon receptor is its role in hepatic glucose output and basal-metabolic-rate signalling, pathways that GLP-1R and GIPR activation do not engage directly.
Clinical-trial data
Each peptide's clinical efficacy data sits in a different development stage, so direct comparison requires care.
Tirzepatide is supported by the SURPASS (type 2 diabetes) and SURMOUNT (obesity) phase 3 programs. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), the 15 mg dose produced 20.9% body-weight reduction at 72 weeks in participants without diabetes. Tirzepatide is the active compound in the marketed products Mounjaro (type 2 diabetes) and Zepbound (obesity, US naming). Research-grade tirzepatide supplied by vendors such as NorexBio is separate from these pharmaceutical preparations and is subject to the same in vitro research-use restrictions as retatrutide.
Retatrutide is in phase 3 (the TRIUMPH program). The principal phase 2 data point is Jastreboff et al., NEJM 2023, which reported 24.2% body-weight reduction at 48 weeks on the 12 mg dose. A separate phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023) reported a 2.02% HbA1c reduction at the same dose. Retatrutide is not approved for human use in any jurisdiction; phase 3 readouts are expected through 2026–2027.
Side-by-side reference
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor profile | GLP-1R + GIPR + GCGR (triple) | GLP-1R + GIPR (dual) |
| Development stage | Phase 3 (TRIUMPH ongoing) | Approved (Mounjaro / Zepbound) |
| Reported peak weight loss | 24.2% at 48 weeks (phase 2, 12 mg) | 20.9% at 72 weeks (phase 3, 15 mg) |
| Principal trial citation | NEJM 2023 (Jastreboff et al.) | NEJM 2022 (Jastreboff et al., SURMOUNT-1) |
| Marketed brand names | None (not approved) | Mounjaro, Zepbound |
In research contexts
Tirzepatide remains the reference compound for any in vitro experiment investigating dual GLP-1 / GIP co-agonism, its receptor profile is well-characterised and the clinical data set is large. Researchers studying the dual-incretin mechanism in cell culture, receptor-binding assays, or comparative pharmacology will typically use tirzepatide as their dual-agonist arm.
Retatrutide is the reference compound for research questions that require glucagon-receptor co-activation alongside GLP-1R and GIPR activity. Examples include in vitro studies of:
- Glucagon-receptor signalling in primary hepatocyte culture in the presence of incretin co-activation.
- Triple-agonist binding affinity and structural characterisation against expressed receptor panels.
- Comparative pharmacology against tirzepatide as the dual-agonist control, isolating the contribution of GCGR activity.
- Analytical method development, HPLC, mass-spectrometry, and stability assays, where the triple-agonist sequence is the target analyte.
Mechanism difference
Both peptides slow gastric emptying, increase glucose-dependent insulin secretion, and reduce appetite signalling at the hypothalamic level. Retatrutide layers on top of that a direct glucagon-receptor effect: increased hepatic glucose output (offset by the GLP-1R-mediated insulinotropic response), increased basal-energy-expenditure signalling, and a different free-fatty-acid handling profile in adipose models. Whether the glucagon-receptor contribution accounts for the higher weight-loss signal in the phase 2 retatrutide data, versus simply a different dose-titration design, is an open research question.
Regulatory and research-use framing
NorexBio supplies retatrutide as a research-grade peptide for in vitro laboratory and analytical research only. Retatrutide is not approved for human or veterinary use anywhere in the EU; product pages, documentation, and communications are restricted to research-use language. The same framing applies to any tirzepatide research material supplied by research-grade vendors. Approved tirzepatide products (Mounjaro / Zepbound) are pharmaceutical preparations supplied through clinical channels under prescription and are out of scope for in vitro research supply. All NorexBio material is for research use only, not for human use.
Which should you order?
If the research question is glucagon-receptor co-activation in the incretin context, retatrutide. If the question is GLP-1 / GIP dual co-agonism without glucagon, tirzepatide. If the question is which molecule has more clinical data, tirzepatide, by a wide margin (full phase 3 program complete and post-approval real-world data available). If the question is which molecule has the highest published single-trial weight-loss figure, retatrutide, by the NEJM 2023 phase 2 data.
NorexBio supplies retatrutide as the single-compound focus of the brand. The order page lists the active 15 mg stock and the 6 mg / 30 mg restocking variants; the science page covers the mechanism in more depth, and the quality page documents the testing pipeline that every lot moves through before release.
